IDH-mutant astrocytomas with these acquired MMR mutations had significantly shorter post-recurrence survival intervals compared to their MMR-wild-type counterparts (17.5 vs. 43.0 months; HR: 3.3 (1.2–8.8); P = .0022) (Figure 4 and Table 2). Here, IDH2 is linked to astrocytoma (excluding glioblastoma).